Acalabrutinib- Redefining Treatment for White Blood Cell Cancers
Acalabrutinib is a second-generation drug designed for treating white blood cell cancers caused by B-cell malignancies.
Cancers of B Cells
B-cell cancers are a type of white blood cell cancer, where genetic changes occur in B lymphocytes, leading to uncontrolled growth and replication of B-cells.
Acalabrutinib Uses in B-Cell Malignancies
- Small lymphocytic lymphoma
- Lymphoma of the Mantle Zone
- Aggressive Non-Hodgkin Lymphoma
How Acalabrutinib Works
- It binds irreversibly to the BTK enzyme
- Blocks the signaling pathway for B-cell proliferation
- Induces apoptosis – B cell death
How Acalabrutinib Differs from First-Generation BTK Inhibitors
Selectivity for BTK
Acalabrutinib selectively blocks the Bruton’s Tyrosine Kinase enzyme, causing irreversible inhibition. B-cell survival signals are completely halted.
Fewer Side Effects
- Due to selective binding, it causes fewer adverse effects on healthy cells.
- Fewer occurrences of arterial fibrillation and bleeding.
Fewer Resistance
Targets a single process without affecting other kinases, effectively blocking the cancer pathway and limiting mutation-driven resistance.
Consistent Blockade
Irreversible and continuous inhibition provides a stable and constant therapeutic response without fluctuations.
Conclusion
Acalabrutinib is a second-generation targeted therapy for white blood cell cancers, offering higher selectivity with reduced side effects and toxicity.
